Revenue and net profit declined year-over-year due to vaccine market contraction and price competition, while blood products showed stable growth. R&D investment increased, and a major vaccine price cut is expected to impact short-term revenue but may drive future market expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.